

A Narrative Review on the Management of Severe COVID-19 Infection Using Stem Cell-Based Therapies with a Focus on the Registered Clinical Trials

Peer-approved: 26 March 2024

© The Author(s) 2024. This is an Open Access article under the CC BY 4.0 license.

Qeios, Vol. 6 (2024)
ISSN: 2632-3834

Negin Mahmoudi¹, Negar Mohammadi Ganjaroudi¹, Alireza Soltani Khaboushan¹, Elham Ahmadi¹, Masoud Bitaraf¹, Asma Laleh², Shayesteh Mehdinejadi³, Masoumeh Majidi Zolbin⁴

1. Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell and Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Iran, Islamic Republic of; 2. Department of Biology, School of Natural Sciences, University of Tabriz, Tabriz, Iran; 3. Department of Reproductive Biology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Iran, Islamic Republic of; 4. Tehran University of Medical Sciences, Iran, Islamic Republic of

The emergence of SARS-CoV-2 has led to a concerning global pandemic. The severity of COVID-19 symptoms may be enhanced due to underlying medical conditions. Several studies have demonstrated that severe COVID-19 infection can lead to innate and adaptive immune dysregulation, hypercytokinemia, as well as the formation of fibro myxoid exudate in the respiratory alveoli, ultimately resulting in pulmonary fibrosis and ARDS as the leading causes of mortality and morbidity. Currently, there is a widespread global endeavor to find efficient drugs or vaccines to manage COVID-19. Although some FDA-approved treatments have been introduced for COVID-19, alternative therapies might decrease mortality rates. Various sources of stem cell-derived exosomes, pluripotent stem cells, and mesenchymal stem cells as cell-based therapies have been applied to moderate to severe COVID-19 patients with ARDS, leading to positive results. Cell-based therapies can probably inhibit tissue remodeling and subsequent end-organ damage by modulating the cytokine cascades and cellular apoptosis. The present review aims to discuss the advantages of stem cell-based therapies in the treatment of COVID-19 patients and the possible challenges associated with their application.

Corresponding author: Masoumeh Majidi Zolbin,
Masoumeh.majidizolbin@gmail.com

Abbreviations

- AAT: Alpha-1-antitrypsin.
- ACE2: Angiotensin convertase enzyme 2.
- ADMSCs: Adipose-derived mesenchymal stem cells.
- ALI: Acute lung injury.
- AlloHSC-iNKT: Allogeneic hematopoietic stem cell-engineered invariant natural killer T cells.
- ARDS: Acute respiratory distress syndrome.
- AT2: Alveolar type 2 pneumocyte.
- bFGF: Basic fibroblast growth factor.
- BM-MSC: Bone marrow-derived mesenchymal stem cell.
- BMP4: Bone morphogenetic protein 4.
- BW: Body weight.
- CCL2: C-C motif chemokine ligand-2.
- c-Myc: cellular-Myc.
- COVID-19: Coronavirus Disease 2019.
- CT-Scan: Computed tomography scan.
- CXCR4: Chemokine receptor 4.
- CXCR7: Chemokine receptor 7.
- CXCL12: C-X-C motif chemokine-12.
- DCs: Dendritic cells.
- 3D-HLO: Three-dimensional human lung organoid.
- DPSC: Dental pulp stem cells.
- ECMO: Extra-corporeal membrane oxygenation.
- EGF: Epidermal growth factor.
- EP2: E-prostanoid 2.
- ESCs: Embryonic stem cells.
- EVs: Extracellular vesicles.
- FDA: United States Food and Drug Administration.
- FGF10: Fibroblast growth factor 10.
- FiO2: Fraction of inspired oxygen.
- GMP: Good Manufacturing Practices.
- hiPSCs: Human-induced pluripotent stem cells.
- HO-1: Heme oxygenase-1.
- hPSCs: Human peripheral blood-derived stem cells.
- hP-MS: Human placenta-derived mesenchymal stem cell.
- HSC: Hematopoietic stem cell.
- hUC-MS: Human umbilical cord-derived mesenchymal stem cells.
- hWJ-MS-S: Human Wharton's Jelly Mesenchymal Stem Cells Secretome.
- IFN-β1: Interferon-β1.
- iNKT cells: Invariant natural killer T cells.
- IL-6: Interleukin-6.
- IL-10: Interleukin 10.
- IL-18: Interleukin-18.
- KGF1: Keratinocyte growth factor 1.
- KLF4: Kruppel-like factor 4.
- MAPK: Mitogen-activated protein kinase.
- MenSCs secretome: Menstrual blood-derived mesenchymal stem cells secretome.
- MMP-1: Matrix metalloproteinase-1.
- MOF: Multiple organ failure.
- MSCs: Mesenchymal stem cells.
- NF-κB: Nuclear factor kappa B.

- NHPBSCs: Non-hematopoietic peripheral blood stem cells.
- NKX2.1: NK2 homeobox 1.
- PaO₂: Partial pressure of oxygen.
- PB plasma/SCs: Peripheral Blood Stem Cells and Plasma stem cells.
- PCL: Polycaprolactone.
- PCR: Polymerase chain reaction.
- PLG: Poly lactide-co-glycolide.
- RA: Retinoic acid.
- SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
- SPO₂: Oxygen Saturation.
- TCR: T cell receptor.
- TGF: Transforming growth factor- β .
- TGF- β 1: Transforming growth factor- β 1.
- TMPRSS2: Transmembrane protease, serine 2.
- UCMSCs: Umbilical cord-derived mesenchymal stem cells.
- VCAM-1: Vascular cell adhesion molecule-1.
- VHD: Graft versus host disease.
- WJ-MSC: Wharton's jelly-derived mesenchymal stem cells.
- WNT: Wingless-related integration site.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to beta-coronaviruses from the Coronaviridae family [1], which recently caused the Coronavirus Disease 2019 (COVID-19) pandemic as a global emergency [2][3]. The coronaviruses have four genera: alpha-, beta-, gamma-, and delta-coronaviruses. Alpha-/beta-coronaviruses are responsible for infections in mammalian species, gamma-coronavirus in avian species, and delta-coronavirus in both avian species and mammals [4][5]. Viral pneumonia resulting from the COVID-19 outbreak was first reported in December 2019 [6]. The helical nucleocapsid protein (N) surrounding the lipid envelopes packs the viral genome [7]. The SARS-CoV-2 binding proteins are characterized by clove-shaped spikes called 'corona'. The binding proteins consist of the host cell receptor-binding subunit (S1) and the host cell membrane-fusion subunits (S2). The aforementioned virus attaches to the human host cell receptors to penetrate the host cell and integrate its genome with that of the host cell to ultimately replicate [8][9]. Despite the high rate of mutation in RNA viruses, SARS-CoV-2, as an RNA virus, has lower mutation rates due to a genome-encoded exonuclease; hence, SARS-CoV-2 has higher adaptivity, leading to more effective human-to-human transmission [10].

The severity of SARS-CoV-2 infection is categorized by symptoms and laboratory findings. A severe case of COVID-19 is characterized by the presence of respiratory distress, oxygen saturation (SPO₂) lower than 93%, and a partial pressure of oxygen (PaO₂) to fraction of inspired oxygen (FiO₂) ratio less than 300 mmHg [11]. COVID-19 can lead to severe complications such as severe thrombocytopenia and multiple organ failure (MOF). Respiratory failure and MOF are the leading causes of mortality in these populations [12][13][14][15].

Although there are comprehensive evaluations of different United States Food and Drug Administration (FDA)-approved therapeutic agents, including hydroxychloroquine, convalescent plasma, interferon- β 1 (IFN- β 1), lopinavir/ritonavir, and remdesivir in the COVID-19 treatment, there are still controversies about their efficacy and safety [16][17]. Several biomaterial-produced agents are studied to strengthen or assist the anti-viral effects of other therapeutic agents, such as silver nanoparticles, and two tetradentate dibasic chelating Schiff base iron III [18][19].

The destructive nature, dangerous complications, and adverse impact on the world economy highlight the necessity of finding a novel and efficient candidate to manage this disease [20], reduce the mortality rate, and achieve better recovery, especially in moderate to severe cases [21]. There has been a growing interest in the use of stem cell-based therapies, including stem cell-derived exosomes, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs), in the treatment of COVID-19 [22][23][24][25]. Human-induced pluripotent stem cells (hiPSCs), which are derived from somatic cells, have been identified as a suitable source for cell therapy, particularly in the context of infectious diseases, compared to other types of stem cells [26]. Additionally, the anti-inflammatory and immunomodulatory properties of MSCs make them an attractive option for treating COVID-19 [27][28][29]. There is a growing interest in stem cell-derived exosome applications trialed as treatment options for COVID-19 due to their lower immunogenicity, stable characteristics, and less invasive harvesting process. Stem cell-derived exosomes can delay the inflammatory effects of the virus by providing immunomodulatory effects or functioning as Nano decoys. The immunomodulatory effects of exosomes can be included as inhibiting the macrophage's TNF- α production, decreasing neutrophil migration, and lowering the lung fibrosis stimulator (Ly6chi monocytes) [25][30][31].

Accordingly, because of the limited data available on the clinical applications of stem cells to manage COVID-19, the present review aims to discuss the advantages and beneficial effects of stem cells, including hiPSCs and MSCs, in the treatment of this infectious disease and the challenges that may arise as a result in this context.

2. Rationale for stem cell-based therapies in COVID-19

Regenerative medicine and tissue engineering are cell-based therapeutic approaches in which the injured tissues and organs are regenerated or replaced using stem cells via cell-loaded and 3-D constructs or platforms [32]. The capability of regulating inflammatory reactions and enhancing tissue repair and regeneration are features of stem cells [33]. Several retrospective studies demonstrated that patients who died of COVID-19 had higher serum concentrations of inflammatory markers such as interleukin-6 (IL-6) [34][35][36]. The hypercytokinemia syndrome, characterized by the hypersecretion of inflammatory cytokines, is responsible for acute cardiac damage, renal failure, acute respiratory distress syndrome (ARDS), air exchange dysfunction, pulmonary edema, and increasing mortality rates in COVID-19 [11][36]. Effective therapeutic options are lacking in cases of severe SARS-CoV-2 infection to ameliorate the respiratory complications and hyperinflammatory syndrome. Current care management in severe cases of COVID-19 pneumonia, such as antiviral drugs, extracorporeal membrane oxygenation (ECMO), and ventilator-assisted oxygenation, cannot reverse the formation of fibromyxoid exudate in respiratory alveoli and subsequent alveolar fibrosis [36][37]. Despite effective therapy, acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in severe SARS-CoV-2 infection. An in vitro study evaluating the characteristics of SARS-CoV-2-exposed induced pluripotent stem cells (iPSCs) demonstrated that the exposed stem cells formed a fibroblast-like phenotype and lost their pluripotency [38]. Several studies depicted that the application of MSCs in ARDS models can decrease alveolar fluid accumulation by repairing and protecting alveolar epithelial and endothelial cells, decreasing endothelial and epithelial permeability, and ultimately ameliorating alveolar fibrosis [36][39][40]. Some of the therapeutic

potentials of stem cell-based therapies in COVID-19 pneumonia are the ability to balance immune responses as well as regulate hypercytokinemia, the recovery of the lung microenvironment, the protection of alveolar epithelial cells, and the alteration of lung dysfunction. Therefore, stem cell-based therapies can be used as an alternative therapy in cases of moderate to severe COVID-19 infection [41]. MSCs could be appropriate candidates to modulate the complications created by SARS-CoV-2 because of their anti-inflammatory and immunomodulatory effects [42]. Determining the type and source of stem cells for therapeutic applications is of great importance in terms of efficacy and safety in COVID-19 treatment [43].

Limited multinational, well-designed studies have been performed to evaluate the precise mechanisms involved in stem cell-based therapies in patients with ARDS or SARS-CoV-2-induced pneumonia. Various studies have faced daunting challenges and limitations in evaluating and interpreting the efficacy of different pharmacological agents in COVID-19 management, such as drug side effects, insignificant suppression of viral loads as the primary outcomes, co-treatments and drug delivery routes, temporary comorbidities, no gender considerations, no placebo-control arm, and small cohort sizes. Stem cell-based therapies could be an alternative route in finding treatment strategies [44][45][46]. Figure 1 depicts an overview of various sources of stem cell application in COVID-19 infection.




Figure 1. An overview of the application of various stem cells in the modeling and treatment of COVID-19. Various types of mesenchymal stem cells and induced pluripotent mesenchymal stem cells can be applied as a platform for COVID-19 in-vitro models for evaluating the effectiveness of different drugs on the diseased model as well as studying underlying pathophysiologic mechanisms. The abbreviations: DPSC, dental pulp stem cells; ADMSC, adipose-derived mesenchymal stem cells; BM-MSC, bone marrow-derived mesenchymal stem cell; P-MSC, placenta-derived mesenchymal stem cell; WJ-MSC, Wharton's jelly-derived mesenchymal stem cells; IV, intravenous; IM, intramuscular.

3. Recent stem cell-based studies in the treatment of COVID-19

Many countries, such as the United States and China, have conducted clinical trials to evaluate the safety and efficacy of stem cell products in treating moderate to severe cases of COVID-19 (Table 1, Table 2). In the conducted clinical trials, stem cells and their products were applied as interventional arms, as shown in Table 1 and Table 2, respectively. There were variable reports of cell doses and protocols. In 28 out of 58 clinical trials, the number of cells used in the interventional arms was based on the patient's weight, whereas in other trials, the number of applied cells was regardless of the patient's weight. Different types of stem cells are being applied as an interventional arm, ranging from embryonic stem cells to mesenchymal stem cells [47][48].

Beneficial therapeutic effects of mesenchymal stem cells in the treatment of COVID-19 are being evaluated by many clinical trials, most of which are injected intravenously, except for 6 clinical trials in which the administration of MSCs and MSC-derived exosomes has been suggested through the inhalation route [7]. Among several clinical trials evaluating the safety and efficacy of stem cell therapy in COVID-19, four completed trials suggested improvements in clinical outcomes without increasing adverse events (Table 1). The completed trials referenced as NCT04473170 and NCT04355728, using non-hematopoietic peripheral blood stem cells (NHPBSCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs), demonstrated improved clinical outcomes without increasing adverse effects, with overall survival rates of 94.20% and 91%, respectively. A study referenced as NCT05019287 depicted that MenSCs secretome could be beneficial in reversing hypoxia and reducing COVID-19 infection mortality rates. The completed clinical trial referenced as IRCT20160809029275N1 demonstrated promising results regarding the presence of recovery in moderate to severe patients receiving more than one dosage of UCMSCs IV injection by forming a significant decrease in inflammatory cytokine levels [49]. The outcomes of conducted clinical trials are categorized into primary and secondary outcomes. The evaluated outcomes through the conducted clinical trials include assessment of the pulmonary index, Sequential Organ Failure Assessment score, inflammatory marker levels, presence and frequency of adverse events, vital signs, clinical symptoms, short-term and long-term mortality rates, duration of ventilator-free days, hospitalization duration, and assessment of radiologic improvement such as the disappearing time of ground glass opacity.

No.	Clinical trial identifier	country	Study design	Study phase	Current status	Source of stem cell	Route of delivery	Number of doses	Single-dose concentration (cells)	Dose intervals	Estimated enrollment
1	NCT04313322	Jordan	single-arm, open-label	phase 1	unknown (previously: recruiting)	WJ-MSCs	IV	3	1* 10 e6 /Kg	3 d	5
2	NCT04473170	United Arab Emirates	double arm, open label	phase 1/phase 2	completed	NHPBSCs	jet nebulization	2	2.2* 10 e6	1 d	146
3	NCT04428801	NM	double arm, double masking	phase 2	not yet recruiting	ADMSCs	IV	3	2* 10 e8	3 d	200
4	NCT04444271	Pakistan	double arm, open label	phase 2	recruiting	BMSCs	NM	2	2* 10 e6 /Kg	7 d	20
5	NCT04336254	China	double arm, triple masking	phase 1/phase 2	recruiting	hDPSCs	IV	3	3* 10 e7	3 d	20
6	NCT04713878	Turkey	triple arm, open-label	not applicable	completed	MSCs	IV	3	1* 10 e6 /Kg	2 d	21
7	NCT04302519	China	single-arm, open-label	early phase 1	unknown (previously: not yet recruiting)	DPMSCs	IV	3	1* 10 e6 /Kg	4 d	24
8	NCT04429763	Colombia	double arm, double masking	phase 2	not yet recruiting	UCMSCs	IV	1	1* 10 e6 /Kg	no intervals	30
9	NCT04486001	USA	single-arm, open-label	phase 1	recruiting	ADMSCs	IV	1	NM	no intervals	20
10	NCT04315987	Brazil	double arm, quadruple masking	phase 2	unknown (previously: not yet recruiting)	MSCs	IV	4	2* 10 e7	2 d	90
11	NCT04416139	Mexico	double arm, open-label	phase 2	Recruiting	MSCs	IV	1	1* 10 e6 /Kg	no intervals	10
12	NCT05017298	NM	double arm, quadruple masking	phase 2	not yet recruiting	ADMSCs	IV	3	2* 10 e8	3 d	30
13	NCT04456361	Mexico	single-arm, open-label	early phase 1	active, not yet recruiting	WJ-MSCs	IV	1	1* 10 e8	no intervals	9
14	NCT04437823	Pakistan	double arm, open label	phase 2	Recruiting	UCMSCs	IV	3	0.5 * 10 e6 /Kg	2 d	20
15	NCT04371601	China	double arm,	early phase 1	active, not yet	UCMSCs	IV	4	1* 10 e6 /Kg	1 d	60

No.	Clinical trial identifier	country	Study design	Study phase	Current status	Source of stem cell	Route of delivery	Number of doses	Single-dose concentration (cells)	Dose intervals	Estimated enrollment
			open-label		recruiting						
16	NCT04611256	Mexico	double arm, open-label	phase 1	Recruiting	ADMSCs	IV	2	1* 10 e6 /Kg	2 d	20
17	NCT04252118	China	double arm, open-label	phase 1	Recruiting	UCMSCs	IV	3	3* 10 e7	3 d	20
18	NCT04346368	China	double arm, a single masking	phase 1/phase 2	not yet recruiting	BMSCs	IV	1	1* 10 e6 /Kg	no intervals	20
19	NCT04273646	China	double arm, open-label	not applicable	not yet recruiting	UCMSCs	IV	4	0.5 * 10 e6 /Kg	2 d	48
20	NCT04366323	Spain	double arm, open-label	phase 1/phase 2	active, not yet recruiting	ADMSCs	NM	2	8* 10 e8	not mentioned	26
21	NCT04625738	France	double arm, quadruple masking	phase 2	Completed	WJ-MSCs	IV	3	first dose: 1* 10 e6 /Kg (maximum: 80 * 10 e6), other doses: 0.5* 10 e6 /Kg (maximum: 40 * 10 e6)	2-3 d	30
22	NCT04905836	USA	double arm, quadruple masking	phase 2	Recruiting	ADMSCs	IV	3	3* 10 e7	2 d	60
23	NCT04992247	NM	double arm, quadruple masking	phase 2	not yet recruiting	ADMSCs	IV	3	1.5* 10 e7	2 d	60
24	NCT04457609	Indonesia	double arm, triple masking	phase 1	Recruiting	UCMSCs	IV	1	1* 10 e6 /Kg	no intervals	40
25	NCT04527224	NM	single-arm, open-label	phase 1/phase 2	not yet recruiting	ADMSCs	NM	NM	NM	NM	10
26	NCT05132972	Indonesia	double arm, quadruple masking	phase 2/ phase 3	Recruiting	UCMSCs	IV	3	1* 10 e6 /Kg	3 d	42
27	NCT04494386	USA	triple arm, triple masking	phase 1/phase 2	Recruiting	UCMSCs	IV	1 or 2	1* 10 e8	2 d	60
28	NCT04339660	China	double arm, triple masking	phase 1/phase 2	Recruiting	UCMSCs	IV	1 or 2	1* 10 e6 /Kg	1 w	30
29	NCT04490486	USA	double arm,	phase 1	not yet recruiting	UCMSCs	IV	2	1* 10 e8	3 d	21

No.	Clinical trial identifier	country	Study design	Study phase	Current status	Source of stem cell	Route of delivery	Number of doses	Single-dose concentration (cells)	Dose intervals	Estimated enrollment
			double masking								
30	NCT04355728	USA	double arm, triple masking	phase 1/phase 2	Completed	UCMSCs	IV	2	1* 10 e8	2 d	24
31	NCT04392778	Turkey	triple arm, quadruple masking	phase 1/phase 2	Completed	MSCs	IV	3	3* 10 e6 /Kg	3 d	30
32	NCT04565665	USA	triple arm, open-label	phase 1/phase 2	Recruiting	UCMSCs	IV	1 or 2	NM	6 d	70
33	NCT488949	Japan	double arm, quadruple masking	phase 2	Recruiting	ADMSCs	IV	4	1* 10 e8	1 w	20
34	NCT04522986	Japan	single arm, open label	phase 1	Completed	ADMSCs	IV	4	1* 10 e8	1 w	6
35	NCT04461925	Ukraine	double arm, open-label	phase 1/phase 2	recruiting	PMMSCs	IV	3	1* 10 e6 /Kg	3 d	30
36	NCT04535856	Indonesia	triple arm, quadruple masking	phase 1	completed	MSCs	IV	1	one arm (low dose group): 5* 10 e7, the other arm (high dose group): 10* 10 e7	no intervals	9
37	NCT04903327	Brazil	double arm, quadruple making	phase 2	recruiting	MSCs	IV	3	3* 10 e7	2 d	100
38	NCT04390152	Colombia	double arm, quadruple masking	phase 1/phase 2	recruiting	WJ-MSCs	IV	2	5* 10 e7	NM	40
39	NCT04629105	USA	quadruple arm, double masking	phase 1	recruiting	MSCs	IV	3	1* 10 e8	NM	70
40	NCT04397796	USA	double arm, quadruple masking	Phase 1	active, not yet recruiting	BMSCs	IV	NM	NM	NM	45
41	NCT04452097	NM	pentad arm, open-label	phase 1/phase 2	not yet recruiting	UCMSCs	IV	1	one arm (low dose group): 0.5* 10 e6 /Kg, the other arm (medium-dose group): 1* 10 e6 /Kg, the other arm (high dose group): 1.5* 10 e6 /Kg	no intervals	39

No.	Clinical trial identifier	country	Study design	Study phase	Current status	Source of stem cell	Route of delivery	Number of doses	Single-dose concentration (cells)	Dose intervals	Estimated enrollment
42	NCT04492501	Pakistan	quadruple arm, open-label	not applicable	completed	BMSCs	IV	1	2* 10 e6 /Kg	no intervals	600
43	NCT04780685	USA	double arm, quadruple masking	phase 2	recruiting	hMSCs	IV	2	NM	2 d	40
44	NCT04331613	China	single-arm, open-label	phase 1/phase 2	unknown (previously: recruiting)	ESCs	IV	1	for dose escalation (3* 10 e6 /Kg, 5* 10 e6 /Kg or 10* 10 e6 /Kg)	no intervals	9
45	NCT04345601	USA	double arm, open label	phase 1/phase 2	recruiting	MSCs*	IV	2	1* 10 e8 /Kg	3 to 5 d	66
46	NCT04390139	Spain	double arm, quadruple masking	phase 1/phase 2	recruiting	WJ-MSCs	IV	2	1* 10 e6 /Kg	2 d	30
47	NCT04447833	Sweden	single arm, open label	phase 1	active, not yet recruiting	BMSCs	IV	1	(3 patients): 1* 10 e6 /Kg, (number of patients): 2* 10 e6 /Kg	no intervals	7
48	NCT04398303	NM	triple arm, double masking	phase 1/phase 2	not yet recruiting	UCMSCs	IV	1	one arm (UCMSCs): 1* 10 e6 /Kg, the other arm (only conditioned medium): 100 ml	no intervals	70
49	NCT04400032	Canada	triple arm, open label	phase 1/phase 2	Completed	UCMSCs	IV	3	one arm: 2.5* 10 e7, the other arm: 5* 10 e7, another arm: 9* 10 e7	1 d	15
50	NCT04467047	NM	single arm, open label	phase 1	not yet recruiting	MSCs*	IV	1	1* 10 e6 /Kg	no intervals	10
51	NCT03042143	United Kingdom	double arm, quadruple masking	phase 1/phase 2	active, not yet recruiting	UCMSCs	IV	1	4* 10 e8	no intervals	120
52	NCT04269525	China	single arm, open label	phase 2	Recruiting	UCMSCs	IV	4	9.9* 10 e7	2 d	16
53	NCT04367077	USA	double arm, quadruple masking	phase 2/phase 3	Recruiting	BMAPCs	IV	1	NM	no intervals	400
54	NCT04333368	France	double arm, triple masking	phase 1/phase 2	Completed	UCMSCs	IV	3	1* 10 e6 /Kg	2 d	47
55	NCT04371393	USA	double arm,	phase 3	active, not yet	MSCs	IV	2	2* 10 e6 /Kg	4 d	223

No.	Clinical trial identifier	country	Study design	Study phase	Current status	Source of stem cell	Route of delivery	Number of doses	Single-dose concentration (cells)	Dose intervals	Estimated enrollment
			triple masking		recruiting						
56	NCT04466098	USA	double arm, triple masking	phase 2	active, not yet recruiting	MSCs	IV	3	3* 10 e8	2 d	9
57	NCT04524962	USA	Single arm, open label	phase 1/phase 2	Recruiting	MSCs RNA-engineered	NM	1	NM	no intervals	30
58	IRCT20160809029275N1	Iran	Single arm, Open label	Phase 1	Completed	UCMSCs	IV	3	1* 10 e6 /Kg	2 D	20

Table 1. Summary of registered clinical trials using stem cell therapy for COVID-19 disease

Abbreviations. No., Number; WJ-MSCs, Warton's jelly-derived mesenchymal stem cells; NM, not mentioned; IV, intravenous; RT-PCR, reverse transcriptase-polymerase chain reaction; NHPBSCs, non-hematopoietic peripheral blood stem cells; SC, stem cell; ADMSCs, adipose-derived mesenchymal stem cells; BMSCs, bone marrow-derived mesenchymal stem cells; hDPSCs, human dental pulp-derived mesenchymal stem cells; MSCs, mesenchymal stem cells; USA, United States of America; DPMSCs, dental pulp-derived

mesenchymal stem cells; UCMSCs, umbilical cord-derived mesenchymal stem cells; MenSCs, menstrual blood-derived mesenchymal stem cells; hMSCs, human mesenchymal stem cells; ESCs, embryonic stem cells; BMAPCs, bone marrow-derived adult progenitor cells; hEKT-Rex-239, human embryonic kidney T-Rex-239 stem cells; Evs, extracellular vesicles; PMMSCs, placenta-derived multipotent mesenchymal stromal cells

No.	Clinical trial identifier	Country	Study design	Study phase	Current status	Source secretome	Route of delivery	Number of doses	Single dose concentration (cells/ Evs)	Dose intervals	Estimated enrollment
1	NCT04602442	Russia	triple arm, double masking	phase 2	enrolling by invitation	MSCs exosomes	inhalation	20	0.5 - 2 * 10 e10 / 3ml solution	Q 12 hrs. for 10 d	90
2	NCT04491240	Russia	triple arm, double masking	phase 1/phase 2	completed	MSCs exosomes	inhalation	20	0.5 - 2 * 10 e10 / 3ml solution	Q 12 hrs. for 10 d	30
3	NCT04798716	USA	quadruple arm, double masking	phase 1/phase 2	not yet recruiting	MSCs exosomes	IV	3	one arm (3 doses, respectively): 2* 10 e9, 4* 10 e9, 8* 10 e9 /ml, the other arm (3 doses, respectively): 8* 10 e9, 4* 10 e9, 8* 10 e9 /ml	1 d	55
4	NCT04276987	China	single-arm, open-label	phase 1	completed	MSCs exosomes	nebulization	5	2* 10 e8 Nano vesicles/ 3 ml	1 d	24
5	NCT05216562	Indonesia	double arm, triple masking	phase 2/phase 3	recruiting	MSCs exosomes	IV	2	NM	6 d	60
6	NCT04969172	Israel	double arm, double masking	phase 2	active, not yet recruiting	hEK-T-Rex-239 exosomes overexpressing CD42	inhalation	5	diluted exosomes / 4 ml NS	Q 24 hrs. for 5 d	155
7	NCT04366063	Iran	triple arm, open label	phase 2/phase 3	recruiting	MSCs + MSCs Evs	IV	one arm: 2 doses of MSCs, the other arm: 2 doses of MSCs + 2 doses of MSCs Evs	one arm: 1* 10 e8 MSCs, the other arm: 1* 10 e8 MSCs + 2 doses of MSCs Evs (not mentioned Evs numbers)	2 d	60
8	NCT04493242	USA	triple arm, triple masking	phase 2	completed	BMSCs Evs	IV	1	one arm: 10 ml / 90 ml NS (8* 10 e11), the other arm: 15 ml / 85 ml NS (1.2* 10 e12)	no intervals	120
9	NCT05125562	USA	triple arm, triple masking	phase 2	not yet recruiting	BMSCs Evs	IV	1	one arm: 10 ml / 90 ml NS (7* 10 e11), the other arm: 15 ml / 85 ml NS (10.5* 10 e11)	no intervals	30
10	NCT04753476	Indonesia	double arm, open-label	phase 2	recruiting	hypoxic MSCs secretome	IV	3	1 ml	1 d (every 12 hrs.)	48
11	NCT05019287	Iran	double arm, double masking	phase 1/phase 2	completed	MenSCs secretome	IV	5	5 ml	1 d	29
12	NCT05122234	Indonesia	double arm, a single masking	phase 3	completed	MSC secretome	IV	1	15 ml / 100 ml NS	no intervals	40

Table 2. Summary of registered clinical trials using stem cell secretome therapy for COVID-19 disease

Abbreviations: No., Number; NM, not mentioned; IV, intravenous; RT-PCR, reverse transcriptase-polymerase chain reaction; SC, stem cell; BMSCs, bone marrow-derived mesenchymal stem cells; MSCs, mesenchymal stem cells; MenSCs, menstrual blood-derived mesenchymal stem cells; Evs, extracellular vesicles; the USA, United States of America.

A study referenced as NCT04473170 evaluated the safety and efficacy of nebulized human peripheral blood-derived stem cells (hPBSCs) in treating symptomatic COVID-19-infected patients, and three nebulization methods were assessed. Among nebulization methods, compressor nebulizers preserve the viability of delivered cells without significant loss in their count and morphologic changes. The mentioned study depicted that the application of hPBSCs has significant improvements in clinical outcomes of the treated group, with a 28-day survival rate of 94.20%. In addition, there was no significant difference in adverse effects between the control and hPBSCs-treated groups [50][51].

Another study referenced as NCT04355728 investigated the safety and efficacy of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in treating severe complications of acute lung injury (ALI) and ARDS, and completed the phase 1/phase 2 trial on 24 patients. The mentioned clinical trial demonstrated that hUC-MSCs treatment would not increase adverse events, with a hazard ratio of 8.76% (95% confidence interval [CI]: 1.07-71.4) and a 31-day survival rate of 91% [52]. A completed clinical trial referenced as NCT04491240 investigating the safety and efficacy of two types of inhaled MSCs exosomes in treating severe hospitalized patients with COVID-19 completed the phase 1/phase 2 trials on 30 patients; it reported no severe adverse events in MSCs exosomes-treated groups [53].

A completed clinical trial referenced as NCT05019287 assessing the safety and efficacy of allogenic menstrual blood-derived mesenchymal stem cells secretome (MenSCs secretome) infusion in treating severe hospitalized patients with COVID-19 completed the phase 1/phase 2 trial on 29 patients; it demonstrated that intravenous injection (IV) of MenSCs secretomes could improve oxygen levels in 60% of the intervention group, decrease radiologic pulmonary involvement, and reduce mortality rates. There were no infusion-related adverse events in MenSCs secretomes-treated groups, with a survival rate of 57% [54].

A study was conducted by Li et al. to assess the effect of invariant natural killer T cells (iNKT) on SARS-CoV-2 infection. They produced allogeneic hematopoietic stem cell-engineered iNKT cells (AlloHSC-iNKT) through T cell receptor (TCR) engineering of human cord blood CD34+ hematopoietic stem cells (HSCs) and differentiation of these HSCs into iNKT cells in an ex vivo HSC-Derived iNKT Cell Culture. The results showed that these AlloHSC-iNKT cells killed SARS-CoV-2-infected cells and eliminated SARS-CoV-2 infection-stimulated inflammatory monocytes. In addition, the AlloHSC-iNKT cells were resistant to T cell-mediated alloreaction and did not cause GVHD [55].

In another study, Liao et al. evaluated the safety and efficacy of interleukin-18-primed hUC-MSCs application in an in vivo model of lung injury. This study demonstrated a more efficient effect of IL-18-primed hUC-MSCs therapy than non-primed hUC-MSCs therapy alone. They found that in the IL-18-primed hUC-MSCs group, the immunosuppressive effect on CD3+ T cells is more prominent. In addition, the IL-18-primed hUC-MSCs expressed higher levels of VCAM-1, MMP-1, TGF- β 1, CCL2, and CXCL12. Also, the in vivo IL-18-primed hUC-MSCs therapy had promising results in improving the clinical symptoms of pre-clinical viral lung injury cases [56].

Also, two separate studies evaluated the in vitro effect of MSCs-derived exosomes. Hussein et al. conducted a study to evaluate the

effect of Human Wharton's Jelly Mesenchymal Stem Cells Secretome (hWJ-MSC-S) on an in vitro model of SARS-CoV-2 infection. The results showed a significant reduction in viral infection as a promising way to overcome SARS-CoV-2 infection and its complications [57]. In addition, in 2022, a study was conducted to evaluate the anti-SARS-CoV-2 effects of extracellular vesicles (EVs) released from MSCs that were applied to in vitro anti-SARS-CoV-2 assays. The result was suppression of viral replication.

The potential and safety of ADMSCs were documented by Sanchez-Guijo et al., who examined 13 adult patients with COVID-19 who underwent invasive mechanical ventilation and were previously treated with antiviral and anti-inflammatory interventions. The administered dose of ADMSCs was 0.98×10^6 cells/kg body weight (BW). The results demonstrated no complications associated with MSC therapy, and clinical improvement was seen in about 70% of the patients discharged from the ICU. Moreover, the MSC therapy elevated the lymphocyte count and reduced the levels of inflammatory markers including CRP, IL-6, ferritin, LDH, and D-dimer; therefore, they suggested ADMSCs therapy as a safe approach with promising clinical outcomes in COVID-19 patients [58].

Further studies need to be conducted to optimize MSCs-based therapies in moderate to severe cases of COVID-19 infection, in terms of the number of cells, administration intervals (single or multiple infusion), source of MSCs, and local (inhalational or nebulized) or systemic route of administration [11][36].




Figure 2. The main characteristics and applications of induced pluripotent stem cells and mesenchymal stem cells are heterogeneous populations derived from somatic cells and pericytes, respectively. These cells are characterized by two properties: the ability to self-renew and the ability to differentiate into different types of cells, with possible clinical potentials in the treatment of COVID-19 patients.

4. Human-induced pluripotent stem cells (hiPSCs)

Adult human somatic cell reprogramming to generate iPSCs using transcription factors was performed by Takahashi et al. [59]. It was reported that iPSCs could be generated from a patient's specific somatic cells to be used in various diseases as an in-vitro disease model [60][61]. One of the recent advances is the somatic cell-derived iPSCs with different clinical applications. The production of iPSCs, an effective cell source in cell therapy, occurs with the entry of a certain class of reprogramming agents into somatic cells [26][60]. Stem cells have been able to restore sperm count in some differentiation studies, so a significant increase was reported in the survival pathways and anti-apoptotic protein expression [62].

Compared to the extraction and employment of embryonic stem cells (ESCs), iPSCs have fewer ethical issues, particularly for autologous stem cell therapy. These cells and ESC-like cells have limited differences in gene expression patterns [63][64]. These cells have the potential for clinical applications and can be produced in different ways. However, the employment of retroviral and lentiviral vectors and proto-oncogenes, such as KLF4 and c-Myc, as well as the approaches applied to reprogram the cells, may impair the developmental characteristics and clinical application of these cells [65].

Anyone with a specific phenotype or genotype can donate hiPSCs for in vitro disease modeling. Differentiated cell types of a particular disease can be achieved from patient-derived hiPSC models. For example, hiPSC-derived cardiomyocytes or neurons can help understand the pathogenesis of particular diseases and screen for the choice of drug [66]. One of the most valuable models for infectious diseases has been reported to be hiPSC-derived cells.

Furthermore, the mixture of human iPSC with recent advancements in the field of gene editing and 3D organoids makes iPSC-based platforms more efficient in every area of their usage, such as precision medicine [67]. The hiPSC can cover human genetic diversity. Despite its ability to produce different types of human cells, it can be used in the drug-production process [68][69].

A study summarized the cytopathogenic impacts and cytokine/chemokine response in hiPSCs-derived cardiomyocytes in an in vitro model of SARS-CoV-2 myocarditis, suggesting an opportunity for drug screening [6]. Huang et al. developed an in vitro study evaluating the key signaling pathway in commencing the SARS-CoV-2 infection as well as assessing the efficacy of anti-viral drugs on the lung organoid platform with an air-fluid culture method. iPSC-derived alveolar type 2 pneumocytes (AT2) are one of the progenitors of the respiratory epithelium that can be infected by SARS-CoV-2. The aforementioned study depicted the predominance of nuclear factor kappa B (NF- κ B) signaling in the first hours of viral invasion as the core inflammatory signaling pathway [70]. Various studies evaluated the viral replication inhibitory effects of different anti-viral drugs such as Remdesivir and the transmembrane protease, serine 2 (TMPRSS2) inhibitor on the SARS-CoV-2 infected models of iPSC-derived lung cells [71][72]. As seen in Figure 2, there are also reports of the ability of lung epithelial cell-derived hiPSCs to produce a sensitive model of SARS-CoV-2 infection and drug screening [73][74]. Several studies were conducted on lung organoids, intestinal organoids, as well as cardiomyocytes iPSCs models and iAT2 iPSCs models as platforms to evaluate the pathophysiology of the SARS-CoV-2 infection mechanisms [74].

5. Mesenchymal Stem Cells (MSCs)

MSCs are fibroblast-like cells with the capacity to attach to plastic surfaces and proliferate in vitro that can be isolated from various sources of fetal or adult tissues [41][75]. Different tissues can be used as a source to isolate MSCs, depending on the practical, logistical, and in vitro properties of the source. Some of these sources are dental pulp, endothelial progenitor cells, umbilical cord blood, adipose tissue, umbilical cord stroma, and bone marrow [33][41]. Adult adipose-derived MSCs (ADMSCs) can repair tissues due to their ability to proliferate for a long time without differentiation [76].

The ability for proliferation and regeneration of MSCs is almost indeterminate and could potentially be used for stem cell therapy in the COVID-19 treatment [77][78]. In response to harsh environmental conditions at the target site, the autophagic and apoptotic processes

of MSCs occur, which eventually results in the release of growth factors and cytokine-rich exosomes, which can reduce disease pathophysiology. Thus, this has shed light on new therapeutic approaches concerning stem cell-derived as a new modality to address the challenges associated with parent cells. Additionally, MSCs are also capable of inhibiting the abnormal activation of T lymphocytes and macrophages, as well as inducing the differentiation of regulatory T cells (Tregs) and anti-inflammatory macrophages [78][79].

Multiple processes are accelerated in the presence of MSCs through some pathways such as chemical absorption, anti-scarring, supporting the growth and differentiation of local stem and progenitor cells, angiogenesis, anti-apoptosis, and immunomodulation [80] through immunomodulation; MSCs could play a role in the repairing and regenerating process in many pathological lung diseases, including idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, acute lung injury, asthma, and bronchopulmonary dysplasia [81].

6. The hiPSCs and hPSCs as In vitro models for COVID-19 treatment

Several limitations became apparent in primary laboratory studies for modeling SARS-CoV-2 as a complex human respiratory disease. Although the drug's effects can be determined directly through patient cells, there are limitations to the availability and expansion capacity of these cells compared to tumor-derived cell lines or immortalized and transformed cells. Besides, genetic and metabolic abnormalities can be a barrier to proper drug screening. Therefore, human cell models must be physiologically appropriate to find out the pathophysiology of SARS-CoV-2, which facilitates drug analysis [73].

The literature review showed that most researchers extracted lung epithelial lineage from hiPSC using a directed differentiation method as a human model through a three-step protocol [82][83]. A microenvironment was remodeled by Activin-A/BMP4 integration to interact with mesenchymal and epithelium cells. Subsequently, the expression of NKX2.1, the main transcription factor in the generation of lung epithelial lineage, was enhanced by increasing the levels of growth factors (EGF and bFGF). Moreover, the proximal airway epithelial cells were generated increasingly by adding retinoic acid (RA), activating KGF1 and WNT pathways, and blocking MAPK and BMP4 pathways. The anterior-posterior endodermal fate was strongly affected by the Wnt/ β -catenin signaling pathway, FGF10, and the lung bud formation and development [84].

Two-dimensional cultured cell lines are the current in vitro systems used to investigate the behavior of different coronaviruses and their drug responses. Because of differences in the infectivity rate of SARS-CoV-2 among different ethnic groups, the application of a three-dimensional human lung organoid (3D-HLO) model isolated from iPSCs of various populations has been suggested recently. The 3D-HLO systems can optimally mimic the normal lung tissue of human beings. The challenge of severity/infectivity rate in human populations precludes the suggestion of animal models as the best option for such studies [85]. Dye et al. designed a 3D-HLO model for adult airways that uses poly (lactide-co-glycolide) (PLG) or polycaprolactone (PCL) scaffolds for HLO transplantation. This protocol provides a porous and degradable scaffold for HLO, so it assists tissue maturation and is an appropriate model for adult airways [86].

In a study by Zhou et al., the iPSCs-derived organoids were introduced as an appropriate infection model to mimic the viral life

cycle and for drug screening under ex vivo conditions. The human iPSC-3D organoids from self-organized tissues having multiple cell environments are functionally and structurally similar to real human organs, thereby providing more efficient viral infection, mimicking regular host-virus interaction, and allowing long-term experiments. A functional hiPSC-derived organoid has been introduced as a feasible and reliable ex vivo model of infection for virological studies, which allows the study of the critical molecular dynamics of SARS-CoV-2 to develop effective treatment and prevention strategies [87].

The researchers developed a platform utilizing system-wide human cell lineages and organoids. They found that both pseudo-entry and live SARS-CoV-2 could infect liver organoids, alpha and beta cells of the pancreas, heart cells, and dopaminergic neurons. As it is still unknown whether SARS-CoV-2 can be vertically transmitted to fetuses, there is a controversy about using hPSC-derived cells to model SARS-CoV-2 infection [88][89].

In a study, Yang et al. [90] assessed the infectivity rate of human cells with SARS-CoV-2 infection via a library generated from hPSC-derived cells and organoids, such as dopaminergic neurons, cortical neurons, microglia, macrophages, cardiomyocytes, endothelial cells, liver organoids, and pancreatic endocrine cells. These results demonstrate that pancreatic, hepatic, and cholangiocyte cells derived from hPSCs are permissive to SARS-CoV-2 infection, as confirmed by adult human islets, liver, and cholangiocyte organoids, as well as a humanized mouse model [90].

The expression of chemokines was upregulated according to the determination of transcript profiles in the hPSC-derived liver organoids and pancreatic endocrine cells infected by SARS-CoV-2, in line with tissue profiling following the autopsy of COVID-19 patients [91]. Low or no permissiveness to both pseudo-entry and live SARS-CoV-2 was interestingly reported for some ACE2-expressing cells by analyzing a human lung single-cell sequencing dataset (GSE132914) for the levels of expression of ACE2 and transmembrane serine protease 2 (TMPRSS2), the two receptors that are the primary sites of entry for SARS-CoV-2 [92].

Including cortical neurons, macrophages, and endothelium, which means factors other than ACE2 are also involved in virus penetration (such as TMPRSS2). The need to replace ACE2-overexpressing cells with hPSC-derived primary-like cells is highlighted in the SARS-CoV-2 biology by looking at the nonlinear relationship between permissiveness to SARS-CoV-2 infection and ACE2 [93]. According to these researchers, drug screening and evaluation of possible antiviral drugs can be done directly using protocols based on disease-relevant human cells/organoids [89].

7. Clinical application of MSCs in the treatment of COVID-19

Much attention has recently been drawn to MSC-based therapies due to their self-renewable capacity and pluripotency [94][95]. The immunoregulatory activity of MSCs mitigates body inflammation via immunosuppression [96][97], which can be a promising possible approach for the treatment of COVID-19 [98]. In an in vitro study, MSCs expressed anti-viral properties, including upregulation of genes resulting in encoding proteins responsible for preventive effects on host cell viral invasions [99]. According to recent findings, there were no critical adverse events, such as ventricular tachycardia, cardiac arrhythmia, and hypoxemia, in nine ARDS patients receiving allogeneic MSC transplantation [100].

The MSCs-based therapy for SARS-CoV-2 was reported to be effective and safe, although further clinical trials with prolonged follow-up

duration are needed to detect the long-term impacts of the treatment on patients with COVID-19 [101]. Chrzanowski et al. reported that the MSCs could repair damaged tissue rapidly owing to their regenerative potential and prevent long-term COVID-19-related lung injuries [7]. In severe SARS-CoV-2 infection, the respiratory alveoli are infiltrated with various immune cells such as neutrophils, macrophages, NK cells, and T cells, leading to high concentrations of inflammatory cytokines and hypercytokinemia. The ultimate consequence of severe infection is alveolar lung fibrosis. The MSCs can stabilize the leakage of endothelial fluid and maintain the activity of the alveolar-capillary barrier. These stem cells can be attracted to the inflammatory sites due to different chemokine secretions, and subsequently transform the overreaction of the inflammatory response. MSCs can ameliorate respiratory alveolar fibrosis due to their regenerative and differentiating characteristics [37]. Several studies evaluating the pathophysiology, molecular signaling, and underlying cellular mechanisms revealed that MSCs can alter the course of moderate to severe COVID-19 infection by following pathways including decreasing recruited cellular apoptosis, direct and indirect immune defense enhancement via secretion of anti-pathogenic peptides and activating phagocytic immune cells, ameliorating oxidative stress, alveolar epithelial regeneration, decreasing the alveolar-capillary permeability, and enhancing alveolar fluid clearance [36]. The ameliorating effect of inflammatory cascades is mostly assigned to the paracrine-releasing factors derived from MSCs; therefore, some studies investigated MSCs' conditioned medium application in in vitro alveolar injury models [102][103]. Due to the lower chance of MSC engraftment, some studies evaluated the therapeutic potentials of MSCs' EVs in ALI models [104][105] as well as clinical trials conducted on COVID-19 patients [57][106].

ADMSCs are one of the MSCs' sources, applied in several clinical trials evaluating their safety and efficacy on moderate to severe COVID-19 patients (Table 1). The rationale for selecting the aforementioned source of MSCs can be due to the less invasiveness of harvesting adipose tissue as well as their higher proliferative ability. ADMSCs, as one of the stromal vascular fractions of human adipose tissue, can have potential anti-viral properties, immunomodulatory effects, as well as inhibitory characteristics on tissue's structural remodeling. The tissue remodeling process in viral infection can be inhibited via increasing the secretion of tissue inhibitors of metalloproteinases using ADMSCs [99][107][108].

A study conducted by Ren et al. depicted that the lung epithelial cells are protected against oxidative stress-induced cell death by delivering miR-21-5p via the MSC exosomes [109]. Bari et al. demonstrated that Alpha-1-antitrypsin (AAT) was present on the surface of exosome-derived MSCs [110]. The anti-inflammatory and immunomodulatory effects of AAT enhanced the protection of lung epithelial cells by inhibiting neutrophil-derived proteolytic enzymes, reducing inflammation-imposed lung permeability, and declining interstitial lung edema [110][111].

Chrzanowski et al. examined female cases with intravenous MSC transplantation (1×10^6 per kg) in lung tissue in comparison with female placebo controls; they observed a significant improvement in pulmonary function. In addition, a significant reduction was seen in tissue inflammation in the intervention group [7].

Although several studies support the evidence that MSCs can be suitable candidates for controlling and treating hypercytokinemia-induced SARS-CoV-2 infection and ALIs due to their critical immunomodulatory, anti-inflammatory, and regenerative properties, respectively [42], there are challenges in optimizing the engraftment and survival of applied MSCs. Several studies are overcoming these

challenges by modifying gene expression to improve MSCs homing or even increasing the anti-inflammatory properties in ALI models [36]. Overexpression of Chemokine receptor 4 (CXCR4), chemokine receptor 7 (CXCR7), and E-prostanoid 2 (EP2) can enhance MSCs migration into the injured respiratory sites [112][113][114]. Heme oxygenase-1 (HO-1) overexpression in MSCs regulates inflammatory cytokine concentration [115].

The clinical trial launched in 2020 to investigate MSC therapy for COVID-19 management revealed a significant elevation in the count of regulatory dendritic cells (DCs) following MSC transplantation [116]. Regulation of the immune system by regulatory DCs is essential to maintaining immune homeostasis by inducing the expression of immunosuppressive cytokines like IL-10 and TGF- β and thus preventing the lungs from the detrimental effects of macrophage and DC-driven systemic immune responses. In addition, the COVID-19 patients with MSC transplantation showed an elevation in IL-10 levels and a reduction in TNF- α levels compared to controls [117]. Furthermore, it is demonstrated that MSC therapy for ARDS caused by H9N2 avian influenza viruses and H5N1 infections results in reduced pulmonary inflammation and lung injuries [118].

In a case series by Yao et al., the efficacy of hUC-MSCs therapy was assessed. Five patients with severe COVID-19 infection underwent the salvage therapy of hUC-MSCs intravenous infusion. The results showed a significant improvement in laboratory biomarkers and lung computed tomography scan (CT-Scan) images in all patients [119].

In addition, two cases were reported by Kim et al. and Balzanelli et al. The first was at Wonju Severance Christian Hospital. The patient was a 73-year-old man with a positive real-time PCR who developed ARDS. Allogenic human bone marrow-derived mesenchymal stem cell (hBMSC) was administered intravenously, and the clinical symptoms, signs, and laboratory findings, including PaO₂/FiO₂ and O₂ saturation, improved [120]. The second case was a 56-year-old man with a positive PCR test for COVID-19 infection who received Peripheral Blood Stem Cells and Plasma (PB plasma/SCs). No adverse effects were reported during PB plasma/SCs administration. Also, CT showed a 98% reduction in lung damage after a total of five plasma transfusions [121].

Shu et al. evaluated the safety and efficacy of UC-MSCs administration in the management of COVID-19. They found the hUC-MSC therapy to be an excellent, effective achievement with clinical value. Moreover, the hUC-MSC therapy group exhibited a significant alleviation of chest tightness, dyspnea, and fatigue in a shorter time compared to the controls [122].

Although multiple MSC-related studies are being performed on COVID-19 patients with respiratory complications, few reports demonstrate the ability of these therapies to promote recovery and survival in these patients. A systematic review that included 8 MSC randomized clinical trials revealed that MSC therapy in COVID-19 cases can reduce mortality rates and hospital stay, and significantly decrease the sensitive markers of inflammation and host-cytokine production response [123]. It can be reasoned that variable factors, including the number of applied MSCs, route of administration, cell infusion intervals, and source of applied MSCs, could play a part in these studies' results [36][124][125]. Antebi et al. depicted that autologous transplantation of BM-MSCs, which are harvested from an ARDS patient, can affect the immunoregulatory properties of harvested MSCs. Although inconclusive evidence is available to support optimized sources of MSC-based therapies for relieving COVID-19 respiratory complications, further studies need to be conducted to optimize MSC-based therapy protocols. The MSCs' route of administration is another factor to be considered in the

interpretation of study results. Miller et al. depicted that the intravenous application of MSCs can significantly decrease ECMO flow due to cell adherence to the oxygenator membrane, indicating the MSCs' intravenous injection before the ECMO application. Local administration of MSCs via the inhalational route can increase the number of transplanted MSCs at the site of injury in ARDS cases, and genetic modification can help to enhance cell engraftment and survival. Several concerns and ethical issues have been raised in the matter of stem cell-derived product application that needs institutional and legislative supervision. The aforementioned concerns can include alterations in biological activity, purification of stem cell-derived products in each cultural batch, and the possibility of adverse and allergic reactions to the remanent cultural media [126]. Despite an urgent need to develop MSC-based therapies during the COVID-19 pandemic, MSC production must be under Good Manufacturing Practices (GMP) and must follow human use regulations before adoption [36][125].

8. Conclusion

Consistent with the findings of the present review article, studies are still ongoing to support stem cell and stem cell-derived strategies as valuable tools for the treatment of COVID-19. There is little evidence so far about the safety and efficacy of such treatments in the short term, at least in severe and very severe patients. Mesenchymal stem cells and human-induced pluripotent stem cells are promising candidates for developing new therapies for COVID-19.

Due to their ability to produce disease-related differentiated cells, these stem cells can be exploited to approve large-scale antiviral drugs as an in vitro model system to scrutinize the biology of virus-host interaction. The complexity and high cost of cell therapies emphasize the careful evaluation of such treatment strategies concerning sensitive parameters, including ICU time, recovery time, and length of hospital stay. Advanced therapies are hardly suitable candidates for controlling the pandemic, but they can still help rescue patients in severe or very severe conditions.

Statements and Declarations

Funding

Not applicable

Conflicts of interest/Competing interests and Author Disclosure Statement

The authors declare no competing interests.

References

1. ^aLi Y, Xu J, Shi W, Chen C, Shao Y, Zhu L, et al. Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. *Stem cell research & therapy*. 2016;7(1):1-11.
2. ^aOrganization WH. WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: World Health Organization; 2020.
3. ^aLivingston E, Bucher K, Rekitto A. Coronavirus Disease 2019 and Influenza 2019-2020. *Jama*. 2020;323(12):1122-.
4. ^aLi F. Structure, function, and evolution of coronavirus spike proteins. *Annual review of virology*. 2016;3:237-61.
5. ^aShirkavand A, Azarkeivan A, Akhavan Tavakkoli M, Magsoudlou M, Arab Khazaeli A, Amin M. Epidemiologic Study of COVID-19 in Iranian Beta-Thalassemia Patients According to Disease Severity. *Arch Clin Infect Dis*. 2023;18(4):e132565.

6. [△]Wong C-K, Luk HK-H, Lai W-H, Lau Y-M, Zhang RR, Wong AC-P, et al. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury. *Circulation Journal*. 2020;CJ-20-0881.
7. [△]Chrzanowski W, Kim SY, McClements L. Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections. *Frontiers in Bioengineering and Biotechnology*. 2020;8:554.
8. [△]Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020;579(7798):265-9.
9. [△]Afzali S, AshtarNakhaei M, Shiari S, Shirkavand A, Farivar S. Human Cell Receptors and Downstream Cascades: A Review of Molecular Aspects and Potential Therapeutic Targets in COVID-19. *Arch Pediatr Infect Dis*. 2021;10(1):e113298.
10. [△]Talaiekhazani A. A Short Communication on COVID-19 Outbreak. *Journal of Infertility and Reproductive Biology*. 2019;7(4):27-8.
11. [△]Can A, Coskun H. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. *Stem Cells Translational Medicine*. 2020;9(11):1287-302.
12. [△]Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York city. *New England Journal of Medicine*. 2020;382(24):2372-4.
13. [△]Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. *New England Journal of Medicine*. 2020;382(23):2268-70.
14. [△]Pleasure SJ, Green AJ, Josephson SA. The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines. *JAMA neurology*. 2020;77(6):679-80.
15. [△]Hashemieh M, Tabatabaee S, Radfar M, Fahim P. COVID-19 associated thrombocytopenia in children: an emerging issue. *International Journal of Pediatrics*. 2021;9(6):13635-42.
16. [△]Li H, Wang Y, Xu J, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. *Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory disease*. 2020;43:E002-E.
17. [△]Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *Jama*. 2020;323(16):1582-9.
18. [△]Al-Radadi NS, Abu-Dief AM. Silver nanoparticles (AgNPs) as a metal nano-therapy: possible mechanisms of antiviral action against COVID-19. *Inorganic and Nano-Metal Chemistry*. 2022;1-19.
19. [△]El-Lateef HMA, Khalaf MM, Shehata MR, Abu-Dief AM. Fabrication, DFT calculation, and molecular docking of two Fe (III) imine chelates as anti-COVID-19 and pharmaceutical drug candidate. *International journal of molecular sciences*. 2022;23(7):3994.
20. [△]Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. *The Lancet Respiratory Medicine*. 2015;3(1):24-32.
21. [△]Choudhery MS, Harris DT. Stem cell therapy for COVID-19: Possibilities and challenges. *Cell biology international*. 2020;44(11):2182-91.
22. [△]Lin Z, Gao Q, Qian F, Jinlian M, Lishi Z, Yu Q, et al. The nucleocapsid protein of SARS-CoV-2 abolished pluripotency in human induced pluripotent stem cells. Available at SSRN 3561932. 2020.
23. [△]Nolasco P, Borsoi J, Moraes CB, Freitas-Junior LH, Pereira LV. Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19. *Genetics and Molecular Biology*. 2021;44(1).
24. [△]Saldanha-Araujo F, Melgaço Garcez E, Silva-Carvalho AE, Carvalho JL. Mesenchymal stem cells: A new piece in the puzzle of COVID-19 treatment. *Frontiers in immunology*. 2020;11:1563.
25. [△]Jamshidi E, Babajani A, Soltani P, Niknejad H. Proposed mechanisms of targeting COVID-19 by delivering mesenchymal stem cells and their exosomes to damaged organs. *Stem Cell Reviews and Reports*. 2021;17:176-92.
26. [△]Amini Mahabadi J, Sabzalipoor H, Kehtari M, Enderami E, Soleimani M, Nikzad H. Derivation of male germ cells from induced pluripotent stem cells by inducers: A review. *Cytotherapy*. 2018;20(3):279-90.
27. [△]Wen Z, Song H, Ming G-L. How does Zika virus cause microcephaly? *Genes & development*. 2017;31(9):849-61.
28. [△]Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. *Diabetes*. 2008;57(7):1759-67.
29. [△]Wada N, Gronthos S, Bartold PM. Immunomodulatory effects of stem cells. *Periodontology 2000*. 2013;63(1):198-216.
30. [△]Popowski KD, Dinh PUC, George A, Lutz H, Cheng K. Exosome therapeutics for COVID-19 and respiratory viruses. *View*. 2021;2(3):20200186.
31. [△]Pereira-Silva M, Chauhan G, Shin MD, Hoskins C, Madou MJ, Martinez-Chapa SO, et al. Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination. *Expert opinion on drug delivery*. 2021;18(10):1395-414.
32. [△]Irmak DK, Darıcı H, Karaoz E. Stem Cell Based Therapy Option in COVID-19: Is It Really Promising? *Aging and disease*. 2020;11(5):1174-91.
33. [△]Behnke J, Kremer S, Shahzad T, Chao C-M, Böttcher-Friebertshäuser E, Morty RE, et al. MSC Based Therapies—New Perspectives for the Injured Lung. *Journal of Clinical Medicine*. 2020;9(3):682.
34. [△]Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? *Nature Reviews Immunology*. 2020;20(5):271-2.
35. [△]Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *Jama*. 2016;315(8):788-800.
36. [△]Hua Q, Andong Z. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. *Protein & Cell*. 2020:707-22.
37. [△]Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, et al. Mesenchymal stem cell therapy for severe COVID-19. *Signal Transduction and Targeted Therapy*. 2021;6(1):339.
38. [△]Lin Z, Gao Q, Qian F, Jinlian M, Lishi Z, Tian C, et al. The nucleocapsid protein of SARS-CoV-2 abolished pluripotency in human induced pluripotent stem cells. Available at SSRN 3561932. 2020.
39. [△]Yang Y, Chen Q-h, Liu A-r, Xu X-p, Han J-b, Qiu H-b. Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway. *Stem cell research & therapy*. 2015;6(1):1-14.
40. [△]Zhao Y-F, Xiong W, Wu X-L. Mesenchymal stem cell-based developmental endothelial locus-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. *Molecular medicine reports*. 2014;9(5):1583-9.
41. [△]Can A, Coskun H. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. *Stem cells translational medicine*. 2020;9(11):1287-302.
42. [△]Fatima F, Ekstrom K, Nazarenko I, Maugeri M, Valadi H, Hill AF, et al. Non-coding RNAs in mesenchymal stem cell-derived extracellular vesicles: deciphering regulatory roles in stem cell potency, inflammatory resolve, and tissue regeneration. *Frontiers in genetics*. 2017;8:161.
43. [△]Lin Z, Wu Z, Mai J, Zhou L, Qian Y, Cai T, et al. The nucleocapsid protein of SARS-CoV-2 abolished pluripotency in human induced pluripotent stem cells. *Biorxiv*. 2020:2020.03.26.010694.

44. ^ΔRussell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *The Lancet*. 2020; 395(10223):473-5.
45. ^ΔStockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS medicine*. 2006;3(9):e343.
46. ^ΔRichardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *The Lancet*. 2020;395(10223):e30-e1.
47. ^ΔClinicalTrials.gov. Safety and Efficacy of CASTem for Severe COVID-19 Associated With/Without ARDS. 2020.
48. ^ΔSong N, Wakimoto H, Rossignoli F, Bhore D, Ciccocioppo R, Chen K-S, et al. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. *Stem Cells*. 2021;39(6):707-22.
49. ^ΔKaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, et al. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. *Stem Cell Research & Therapy*. 2022;13(1):283.
50. ^ΔCastillo Aleman YM, Villegas Valverde CA, Ventura Carmenate Y, Abdel Hadi L, Rivero Jimenez RA, Rezgui R, et al. Viability assessment of human peripheral blood-derived stem cells after three methods of nebulization. *Am J Stem Cells*. 2021;10(4):68-78.
51. ^ΔVentura-Carmenate Y, Alkaabi FM, Castillo-Aleman YM, Villegas-Valverde CA, Ahmed YM, Sanna P, et al. Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020. *Transl Med Commun*. 2021;6(1):25.
52. ^ΔLanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. *Stem cells translational medicine*. 2021;10(5):660-73.
53. ^ΔTyumina O. Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia. 2020.
54. ^ΔFathi-Kazerooni M, Fattah-Ghazi S, Darzi M, Makarem J, Nasiri R, Salahshour F, et al. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. *Stem Cell Res Ther*. 2022;13(1):96.
55. ^ΔLi Y-R, Dunn ZS, Garcia Jr G, Carmona C, Zhou Y, Lee D, et al. Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. *Stem cell research & therapy*. 2022;13(1):112.
56. ^ΔLiao Y, Fu Z, Huang Y, Wu S, Wang Z, Ye S, et al. Interleukin-18-prime d human umbilical cord-mesenchymal stem cells achieve superior therapeutic efficacy for severe viral pneumonia via enhancing T-cell immunosuppression. *Cell Death & Disease*. 2023;14(1):66.
57. ^ΔHussein MA, Hussein HA, Thabet AA, Selim KM, Dawood MA, El-Adly AM, et al. Human Wharton's jelly mesenchymal stem cells secrete and inhibit human SARS-CoV-2 and avian infectious bronchitis coronavirus. *Cells*. 2022;11(9):1408.
58. ^ΔSánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata-Martínez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. *Eclinical Medicine*. 2020;25:100454.
59. ^ΔTakahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *cell*. 2007;131(5):861-72.
60. ^ΔMahabadi JA, Sabzalipour H, Bafrani HH, Gheibi Hayat SM, Nikzad H. Application of induced pluripotent stem cell and embryonic stem cell technology to the study of male infertility. *Journal of cellular physiology*. 2018;233(11):8441-9.
61. ^ΔLiu S, Xu Y, Zhou Z, Feng B, Huang H. Progress and challenges in generating functional hematopoietic stem/progenitor cells from human pluripotent stem cells. *Cytotherapy*. 2015;17(4):344-58.
62. ^ΔBeeram E. Hormonal effect on male fertility and stem cell survival. *Journal of Infertility and Reproductive Biology*. 2019;7(1):4-7.
63. ^ΔChin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. *Cell stem cell*. 2009;5(1):111-23.
64. ^ΔMahabadi JA, Sabzalipour H, Nikzad H, Seyedhosseini E, Enderami SE, Gheibi Hayat SM, et al. The role of microRNAs in embryonic stem cell and induced pluripotent stem cell differentiation in male germ cells. *Journal of cellular physiology*. 2018.
65. ^ΔLee H, Park J, Forget BG, Gaines P. Induced pluripotent stem cells in regenerative medicine: an argument for continued research on human embryonic stem cells. *Regen Med*. 2009;4(5):759-69.
66. ^ΔNolasco P, Borsoi J, Moraes CB, Freitas-Junior LH, Pereira LV. Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19. *Genetics and Molecular Biology*. 2020;44(1).
67. ^ΔShi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. *Nature reviews Drug discovery*. 2017;16(2):115-30.
68. ^ΔTurner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, et al. Toward the development of a global induced pluripotent stem cell library. *Cell stem cell*. 2013;13(4):382-4.
69. ^ΔAmini Mahabadi J, Karimian M, Aghighi F, Enderami SE, Seyyed Hosseini E, Talaei SA, et al. Retinoic acid and 17 β -estradiol improve male germ cell differentiation from mouse-induced pluripotent stem cells. *Andrologia*. 2020;52(2):e13466.
70. ^ΔHuang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos K-D, et al. SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. *Cell Stem Cell*. 2020;27(6):962-73. e7.
71. ^ΔEastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS central Science*. 2020;6(5):672-83.
72. ^ΔShi R, Shan C, Duan X, Chen Z, Liu P, Song J, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature*. 2020;584(7819):120-4.
73. ^ΔSurendran H, Nandakumar S, Pal R. Human induced pluripotent stem cell-derived lung epithelial system for SARS-CoV-2 infection modeling and its potential in drug repurposing. *Stem cells and development*. 2020;29(21):1365-9.
74. ^ΔLuo Y, Zhang M, Chen Y, Chen Y, Zhu D. Application of human induced pluripotent stem cell-derived cellular and organoid models for COVID-19 research. *Frontiers in Cell and Developmental Biology*. 2021;9:720099.
75. ^ΔNaji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. *Cellular and Molecular Life Sciences*. 2019;76(17):3323-48.
76. ^ΔRatajczak MZ, Marycz K, Poniewierska-Baran A, Fiedorowicz K, Zbucka-Kretowska M, Moniuszko M. Very small embryonic-like stem cells as a novel developmental concept and the hierarchy of the stem cell compartment. *Advances in Medical Sciences*. 2014;59(2):273-80.
77. ^ΔYang J, Jia Z. Cell-based therapy in lung regenerative medicine. *Regenerative medicine research*. 2014;2(1):1-7.
78. ^ΔLin F, Ichim TE, Pingle S, Jones LD, Kesari S, Ashili S. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome. *World J Stem Cells*. 2020;12(10):1067-79.

79. [△]Tsuchiya A, Takeuchi S, Iwasawa T, Kumagai M, Sato T, Motegi S, et al. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. *Infla mm Regen*. 2020;40:14-.
80. [△]Lasocka I, Jastrzebska E, Szulc-Dąbrowska L, Skibniewski M, Paster nak I, Kalbacova MH, et al. The effects of graphene and mesenchyma l stem cells in cutaneous wound healing and their putative action me chanism. *International journal of nanomedicine*. 2019;14:2281.
81. [△]Xu T, Zhang Y, Chang P, Gong S, Shao L, Dong L. Mesenchymal stem cell-based therapy for radiation-induced lung injury. *Stem cell resear ch & therapy*. 2018;9(1):1-7.
82. [△]Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos K-D, et al. SARS-CoV-2 infection of pluripotent stem cell-derive d human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic i nflammatory response. *Cell Stem Cell*. 2020;27(6):962-73.
83. [△]Banerjee P, Surendran H, Bharti K, Morishita K, Varshney A, Pal R. L ong Noncoding RNA RP11-380D23. 2 Drives Distal-Proximal Patterni ng of the Lung by Regulating PITX2 Expression. *Stem Cells*. 2018;36 (2):218-29.
84. [△]Han Y, Yang L, Duan X, Duan F, Nilsson-Payant BE, Yaron TM, et al. I dentification of candidate COVID-19 therapeutics using hPSC-derive d lung organoids. *BioRxiv*. 2020.
85. [△]Bose B. Induced Pluripotent Stem Cells (iPSCs) Derived 3D Human L ung Organoids from Different Ethnicities to Understand the SARS-Co V2 Severity/Infectivity Percentage. *Stem Cell Reviews and Reports*. 2 020:1-3.
86. [△]Dye BR, Youngblood RL, Oakes RS, Kasputis T, Clough DW, Spence J R, et al. Human lung organoids develop into adult airway-like struct ures directed by physico-chemical biomaterial properties. *Biomateri als*. 2020;234:119757.
87. [△]Zhou H, Liu L-P, Fang M, Li Y-M, Zheng Y-W. A potential ex vivo infe ction model of human induced pluripotent stem cell-3D organoids be yond coronavirus disease 2019. *Histology and histopathology*. 2020:1 8223-.
88. [△]Lamoureux A, Attie-Bitach T, Martinovic J, Lerez-Ville M, Ville Y. E vidence for and against vertical transmission for severe acute respira tory syndrome coronavirus 2. *American Journal of Obstetrics and Gy necology*. 2020;223(1):91. e1-. e4.
89. [△]Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 t ropism and model virus infection in human cells and organoids. *Cell stem cell*. 2020;27(1):125-36. e7.
90. [△]Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, et al. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV- 2 Tropism and Model Virus Infection in Human Cells and Organoids. *Cell Stem Cell*. 2020;27(1):125-36. e7.
91. [△]Memon B, Abdelalim EM. Stem cell therapy for diabetes: beta cells v ersus pancreatic progenitors. *Cells*. 2020;9(2):283.
92. [△]Zhou L, Niu Z, Jiang X, Zhang Z, Zheng Y, Wang Z, et al. SARS-CoV-2 Targets by the pscRNA Profiling of ACE2, TMPRSS2 and Furin Protea ses. *iScience*. 2020;23(11):101744.
93. [△]Yiangou L, Davis RP, Mummery CL. Using Cardiovascular Cells fro m Human Pluripotent Stem Cells for COVID-19 Research: Why the He art Fails. *Stem cell reports*. 2020.
94. [△]Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal stem cell s for regenerative medicine. *Cells*. 2019;8(8):886.
95. [△]Le Blanc K, Davies LC. MSCs—cells with many sides. *Cytotherapy*. 2 018;20(3):273-8.
96. [△]de Castro LL, Lopes-Pacheco M, Weiss DJ, Cruz FF, Rocco PRM. Curr ent understanding of the immunosuppressive properties of mesench ymal stromal cells. *Journal of Molecular Medicine*. 2019;97(5):605-18.
97. [△]Saldaña L, Bensiamar F, Vallés G, Mancebo FJ, García-Rey E, Vilaboa N. Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors. *Stem cell research & therapy*. 2019;10(1):1-15.
98. [△]Khoury M, Rocco PR, Phinney DG, Krampera M, Martin I, Viswanat han S, et al. Cell-based therapies for COVID-19: proper clinical investi gations are essential. *Cytotherapy*. 2020.
99. [△]Gentile P, Sterodimas A, Pizzicannella J, Calabrese C, Garcovich S. Research progress on mesenchymal stem cells (MSCs), adipose-deriv ed mesenchymal stem cells (AD-MSCs), drugs, and vaccines in inhibit ing COVID-19 disease. *Aging and disease*. 2020;11(5):1191.
100. [△]Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, et al. Clinical study using mesenchymal stem cells for the treatment of patients with seve re COVID-19. *Frontiers of medicine*. 2020;14(5):664-73.
101. [△]Raza SS, Khan MA. Mesenchymal Stem Cells: A new front emerge in COVID19 treatment: Mesenchymal Stem Cells therapy for SARS-CoV2 viral infection. *Cytotherapy*. 2020.
102. [△]Chen J, Li Y, Hao H, Li C, Du Y, Hu Y, et al. Mesenchymal stem cell con ditioned medium promotes proliferation and migration of alveolar e pithelial cells under septic conditions in vitro via the JNK-P38 signali ng pathway. *Cellular Physiology and Biochemistry*. 2015;37(5):1830-4 6.
103. [△]Goolaeerts A, Pellán-Randrianarison N, Larghero J, Vanneaux V, Uzu nhan Y, Gille T, et al. Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury. *American Journal of Physi ology-Lung Cellular and Molecular Physiology*. 2014;306(11):L975-L8 5.
104. [△]Zhu Y-g, Feng X-m, Abbott J, Fang X-h, Hao Q, Monsel A, et al. Huma n mesenchymal stem cell microvesicles for treatment of Escherichia c oli endotoxin-induced acute lung injury in mice. *Stem cells*. 2014;32 (1):116-25.
105. [△]Tang X-D, Shi L, Monsel A, Li X-Y, Zhu H-L, Zhu Y-G, et al. Mesench ymal stem cell microvesicles attenuate acute lung injury in mice partl y mediated by Ang-1 mRNA. *Stem cells*. 2017;35(7):1849-59.
106. [△]Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, Makarem J, Nasiri R, S alahshour F, et al. Safety and efficacy study of allogeneic human me nstrual blood stromal cells secretome to treat severe COVID-19 patien ts: clinical trial phase I & II. *Stem Cell Research & Therapy*. 2022;13(1): 96.
107. [△]Gentile P. SARS-CoV-2: the “uncensored” truth about its origin and a dipose-derived mesenchymal stem cells as new potential immune-m odulatory weapon. *Aging and disease*. 2021;12(2):330.
108. [△]Gentile P, Sterodimas A. Adipose stem cells (ASCs) and stromal vasc ular fraction (SVF) as a potential therapy in combating (COVID-19)-d isease. *Aging and disease*. 2020;11(3):465.
109. [△]Ren W, Hou J, Yang C, Wang H, Wu S, Wu Y, et al. Extracellular vesicle s secreted by hypoxia pre-challenged mesenchymal stem cells promo te non-small cell lung cancer cell growth and mobility as well as mac rophage M2 polarization via miR-21-5p delivery. *Journal of Experime ntal & Clinical Cancer Research*. 2019;38:1-14.
110. [△]Bari E, Ferrarotti I, Di Silvestre D, Grisoli P, Barzon V, Balderacchi A, et al. Adipose mesenchymal extracellular vesicles as alpha-1-antit rypsin physiological delivery systems for lung regeneration. *Cells*. 201 9;8(9):965.
111. [△]Bhattacharya J, Matthay MA. Regulation and repair of the alveolar -capillary barrier in acute lung injury. *Annual review of physiology*. 2013;75:593-615.
112. [△]Shao Y, Zhou F, He D, Zhang L, Shen J. Overexpression of CXCR7 pro motes mesenchymal stem cells to repair phosgene-induced acute lun g injury in rats. *Biomedicine & Pharmacotherapy*. 2019;109:1233-9.

113. [△]Yang J-X, Zhang N, Wang H-W, Gao P, Yang Q-P, Wen Q-P. CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats. *Journal of Biological Chemistry*. 2015;290(4):1994-2006.
114. [△]Han J, Li Y, Li Y. Strategies to enhance mesenchymal stem cell-based therapies for acute respiratory distress syndrome. *Stem cells international*. 2019;2019.
115. [△]Chen X, Zhang Y, Wang W, Liu Z, Meng J, Han Z. Mesenchymal stem cells modified with heme oxygenase-1 have enhanced paracrine function and attenuate lipopolysaccharide-induced inflammatory and oxidative damage in pulmonary microvascular endothelial cells. *Cellular Physiology and Biochemistry*. 2018;49(1):101-22.
116. [△]Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. *Aging and disease*. 2020;11(2):216.
117. [△]Liu X, Qu X, Chen Y, Liao L, Cheng K, Shao C, et al. Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. *The Journal of Immunology*. 2012;189(3):1182-92.
118. [△]Chan MC, Kuok DJ, Leung CY, Hui KP, Valkenburg SA, Lau EH, et al. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. *Proceedings of the National Academy of Sciences*. 2016;113(13):3621-6.
119. [△]Yao W, Jiang Y, Yuan Q, Wu W, Hou R, Qi Q, et al. The salvage therapy utilizing human umbilical cord-derived mesenchymal stem cells to treat severe COVID-19 patients: case series. 2023.
120. [△]Kim K, Bae KS, Kim HS, Lee W-Y. Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19-Induced ARDS Patients: A Case Report. *Medicina*. 2022;58(12):1698.
121. [△]Balzanelli MG, Distratis P, Lazzaro R, D'Ettorre E, Nico A, Inchingolo F, et al. New translational trends in personalized medicine: autologous peripheral blood stem cells and plasma for COVID-19 patient. *Journal of Personalized Medicine*. 2022;12(1):85.
122. [△]Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. *Stem cell research & therapy*. 2020;11(1):1-11.
123. [△]Yan C, Hu M, Dai R. Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis. *Immunology, Inflammation and Disease*. 2023;11(9):e1000.
124. [△]Generali M, Kehl D, Wanner D, Okoniewski MJ, Hoerstrup SP, Cinelli P. Heterogeneous expression of ACE2 and TMPRSS2 in mesenchymal stromal cells. *Journal of Cellular and Molecular Medicine*. 2022;26(1):228-34.
125. [△]Mazini L, Ezzoubi M, Malka G. Overview of current adipose-derived stem cell (ADSCs) processing involved in therapeutic advancements: flow chart and regulation updates before and after COVID-19. *Stem cell research & therapy*. 2021;12(1):1-17.
126. [△]Li S, Zhu H, Zhao M, Liu W, Wang L, Zhu B, et al. When stem cells meet COVID-19: recent advances, challenges and future perspectives. *Stem Cell Research & Therapy*. 2022;13:1-16.

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.